AstraZeneca Pharma India Limited will launch Breztri Aerosphere in January 2025 in India.
Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).
The company earlier in December 2023 received the Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere).
Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 6497.50 as compared to the previous close of Rs. 6397.65. The total number of shares traded during the day was 6312 in over 620 trades.
The stock hit an intraday high of Rs. 6588.35 and intraday low of 6450.05. The net turnover during the day was Rs. 41086507.00. |
